Background: Infections caused by MDR Pseudomonas aeruginosa are on the rise, particularly in critically ill patients. Therefore, there is a need to evaluate new antimicrobial regimens. The objectives of this study were to investigate the ceftolozane/tazobactam resistance rates of MDR and XDR P. aeruginosa, the underlying resistance genes, the clonal structure and different antimicrobial susceptibility testing (AST) methods regarding their accuracy for ceftolozane/tazobactam testing.
Introduction
MDR Pseudomonas aeruginosa are among the most significant threats resulting from antibiotic resistance and these infections are associated with an increased morbidity and mortality. 1 Since therapeutic options for the treatment of resistant P. aeruginosa infections are decreasing, there is an interest in exploring new antimicrobial regimens. In 2014 and 2015, the US FDA and the EMA approved ceftolozane/tazobactam, respectively, for the treatment of complicated urinary tract and abdominal infections. Compared with ceftazidime, ceftolozane/tazobactam is more stable against AmpC b-lactamase, has a higher affinity for P. aeruginosa penicillinbinding proteins, can effectively cross the outer membrane in the absence of outer-membrane porins and acts in the periplasm even in the presence of efflux pumps. 1 Therefore, the fixed combination of ceftolozane/tazobactam is a promising drug in the treatment of infections caused by MDR P. aeruginosa. However, ceftolozane/ tazobactam is not effective in MBL-producing isolates. 1 A reliable detection of resistance or susceptibility to ceftolozane/tazobactam in MDR isolates is essential in order to consider this antibiotic as a potential therapeutic option.
The objectives of our study were to assess: (i) the ceftolozane/ tazobactam resistance rates of MDR and XDR P. aeruginosa; (ii) the underlying resistance genes; and (iii) the clonal structure. We further investigated different antimicrobial susceptibility testing (AST) methods regarding their accuracy for ceftolozane/tazobactam testing.
Materials and methods

Bacterial isolates
Isolates were collected from routine microbiological diagnostics performed at the University Hospital Münster, Germany between 2013 and 2016.
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Routine susceptibility testing was done using Vitek 2 automated system (bioMérieux, Marcy-l' Etoile, France) and EUCAST clinical breakpoints (version 7.0). In Germany, the resistance patterns of P. aeruginosa are currently classified as 3 or 4 MRGN (MDR Gram-negative bacteria) if they are resistant to three or four of the following agents: piperacillin, ceftazidime/cefepime, meropenem/imipenem and ciprofloxacin. 2 These isolates (3 and 4 MRGN P. aeruginosa) were retested by the broth microdilution (BMD) method using Micronaut-S 96-well microtitre plates (Merlin, Bornheim-Hersel, Germany) against multiple P. aeruginosa active antibiotics (i.e. piperacillin/ tazobactam, aztreonam, ceftazidime, cefepime, meropenem, imipenem, amikacin, gentamicin, tobramycin, colistin, ciprofloxacin, levofloxacin). Based on the BMD test results, isolates were classified as MDR or XDR according to criteria suggested by a joint initiative of the ECDC and the CDC (Figure 1) . 3 Resistance to 'at least one agent in three or more antimicrobial categories' defines MDR. 3 Isolates are XDR if 'at least one agent in all but two or fewer antimicrobial categories' is non-susceptible. 3 Only isolates meeting the definition of MDR and XDR were included. Exclusion criteria were: (i) duplicate isolates from one patient; (ii) epidemiologically related P. aeruginosa; and (iii) isolates from patients with cystic fibrosis. The latter were considered as a bias due to frequent and often prolonged antimicrobial treatment.
Antimicrobial susceptibility testing
All tests were performed in triplicate. The MIC of ceftolozane (MSD Sharp & Dohme GmbH, Haar, Germany) with tazobactam (Sigma-Aldrich, Taufkirchen, Germany) was determined by the BMD reference method in accordance with the ISO 20776-1 and CLSI guidelines using cationadjusted Mueller-Hinton broth (BD Diagnostics, Heidelberg, Germany). 4, 5 The ceftolozane concentrations ranged from 0.03 to 256 mg/L in 2-fold dilution steps, whereas the tazobactam concentration was fixed at 4 mg/L as recommended by CLSI and EUCAST. 6, 7 Gradient diffusion testing was performed using MIC Test Strips Disc diffusion was performed in accordance with EUCAST using 30/10 lg ceftolozane/tazobactam discs (MAST Diagnostica, Reinfeld, Germany) on Mueller-Hinton agar (BD Diagnostics). For disc diffusion zone diameters, mean values were calculated. As EUCAST breakpoints are not yet available for ceftolozane/tazobactam disc diffusion in Pseudomonas spp., we used the respective CLSI breakpoints (susceptible, 21 mm; intermediate, 17-20 mm; resistant, 16 mm). 6 P. aeruginosa ATCC 27853 and Escherichia coli ATCC 35218 were used as quality control (QC) strains and were within the QC range throughout the study.
MBL gene detection
All isolates were screened for the presence of selected MBL-encoding genes (i.e. bla VIM 1-37 , bla NDM 1-7 ) using isothermal amplification (Eazyplex SuperBug, Amplex, Giessen, Germany). The MBL gene bla IMP was detected by conventional PCR. 8 WGS was done for a subset of ceftolozane/ tazobactam-resistant isolates to screen for additional and uncommon b-lactamase genes including MBL genes from environmental bacteria (bla AIM , bla CAR , bla CAU , bla DIM , bla FEZ , bla FIM , bla FRI , bla GES , bla GIM , bla GOB , bla HMB-1 , bla KHM-1 , bla L1 , bla PER , bla POM , bla SIM , bla SME , bla SPM , bla THIN-B , bla VEB ).
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WGS
To assess the clonal structure of the investigated P. aeruginosa MDR and XDR isolates, we performed WGS. For that purpose, we randomly selected at least 50% of isolates from each year using an online randomization tool (www.randomizer.org). Sequencing library preparation and sequencing on either an Illumina MiSeq or NextSeq sequencing platform (Illumina Inc., San Diego, CA, USA) were done as published. 15 Data analysis comprising de novo assembly and genome-wide typing based on gene-by-gene comparisons [i.e. core genome MLST (cgMLST)] were performed using SeqSphere ! software version 3.0 (Ridom GmbH, Münster, Germany) and an ad hoc cgMLST scheme for P. aeruginosa targeting up to 3842 genes. 15 Only WGS datasets with 95% extracted cgMLST targets were analysed. A minimum To classify these isolates according to international criteria, susceptibility testing of these isolates was repeated using broth microdilution. Only isolates meeting the criteria for MDR or XDR were included in the final analysis.
spanning tree was constructed using SeqSphere ! . For backwards compatibility, MLST STs were in silico deduced from the de novo assemblies.
Raw reads are deposited at the European Nucleotide Archive (ENA) under study accession number PRJEB20248.
Statistical analysis
The v 2 test ('R', package 'epiDisplay', significance level " 0.05) was used to assess the distribution of resistance rates between groups and to estimate OR and 95% CI. The 95% CI of error rates (major errors and minor errors) and the categorical agreement of different testing methods were calculated using the Wilson procedure without a correction for continuity. The agreement between MICs from broth microdilution and gradient diffusion test was analysed using a Bland-Altman plot.
Results
In total, 125 non-duplicate P. aeruginosa isolates collected between 2013 and 2016 were eligible. Of these, 13 were excluded because they did not meet the criteria of MDR and XDR or derived from a patient with cystic fibrosis (Figure 1) . The remaining 112 isolates (MDR, n " 44; XDR, n " 68) were included in the final analysis. They represent a cross-section of isolates from outpatient departments (n " 6), intensive care (n " 42), intermediate care (n " 19) and normal care units (n " 45). They were associated with colonization (41.1%, n " 46) or infection (58.9%, n " 66). The most frequent specimens from infected patients were blood cultures (n " 14), wound swabs (n " 11) or urines (n " 11).
In total, 38 isolates (33.9%) were resistant to ceftolozane/tazobactam according to the BMD reference method ( Table 1) . The MIC 50 , MIC 90 and MIC range of ceftolozane/tazobactam determined by BMD were 2, 256 and 0.5 to .256 mg/L, respectively (Table 1) . Resistance was significantly lower in MDR P. aeruginosa (4.8%) compared with XDR P. aeruginosa (50%, OR " 0.1, 95% CI " 0.03-0.31, P , 0.0001; see also Table S1 , available as Supplementary data at JAC Online). All isolates from bone marrow transplant units (n " 17, 100%) were resistant to ceftolozane/ tazobactam. In all other departments, the proportion of ceftolozane/tazobactam-resistant isolates ranged between 16.7% (n " 1, outpatient departments) and 26.2% (n " 11, ICUs).
The most common carbapenemase among all 112 MDR and XDR P. aeruginosa isolates was bla IMP (n " 25, 22.3%), followed by bla VIM (n " 4, 3.6%) and bla GES (n " 1). The underlying mechanism in ceftolozane/tazobactam-resistant isolates (n " 38) was bla IMP (n " 25), bla VIM (n " 4) and bla GES (n " 1). The remaining eight ceftolozane/tazobactam-resistant isolates were negative for bla AIM , bla CAR , bla CAU , bla DIM , bla FEZ , bla FIM , bla FRI , bla GES , bla GIM , bla GOB , bla HMB-1 , bla IMP , bla KHM-1 , bla KPC , bla L1 , bla NDM, bla PER , bla POM , bla SIM , bla SME , bla SPM , bla THIN-B , bla VEB and bla VIM .
Of the 112 isolates, 77 were randomly selected for WGS (Table S2) . Sequencing coverage (37-to 163-fold, mean 68), number of contigs (123-667, mean 286), 95% (mean 98.3%) extracted cgMLST targets, STs and cgMLST allelic profiles are listed in Table S2 . In total, 34 different STs were detected; the predominant ST was ST235 (n " 19, 24.7%) followed by ST274 and ST395 (n " 6, 7.8%, each). Figure 2 displays the diversity of the MDR and XDR isolates, based on cgMLST allelic profiles. Ceftolozane/tazobactam resistance was significantly associated with ST235 (P , 0.001). However, ceftolozane/tazobactam-resistant isolates were also found in unrelated STs.
The gradient diffusion test categorized 67/112 (59.8%) isolates as susceptible, which is fewer compared with the BMD reference method (66.1%). Seven isolates were falsely categorized as resistant compared with BMD, constituting 7/112 (6.3%, 95% CI " 3.1%-12.3%) of all isolates or 7/74 (9.5%, 95% CI " 4.6%-18.3%) of isolates tested susceptible by the reference method (major error rate). There were no false-susceptible results (very major errors). The overall categorical agreement (CA) was 93.8% (95% CI " 87.6%-96.9%). Essential agreement (EA; MIC result within + one doubling dilution step compared with the MIC determined with the reference method) was 78.6% (95% CI " 70.1%-85.1%). The MIC 50 , MIC 90 and MIC range of ceftolozane/tazobactam determined by the gradient diffusion method were 2, 256 and 0.5 to .256 mg/L, respectively. The Bland-Altman analysis revealed a good agreement between BMD and the gradient diffusion test at low ceftolozane concentrations, but results markedly differed at higher concentrations (128 mg/L; Figure S1 ).
The disc diffusion method categorized 71 (63.4%) isolates as susceptible, 7 (6.3%) as intermediate and 34 (30.4%) as resistant. The mean inhibition zone diameter was 21 mm (range " 6-33 mm). The result for one isolate was false-resistant, i.e. 1/112 (0.9% of all isolates, 95% CI " 0.2%-4.9%) or 1/74 (1.4% of isolates susceptible according to BMD, 95% CI" 0.2%-7.3%, major error rate). Minor errors (false categorization involving intermediate result) were documented in 7/112 (6.3%, 95% CI " 3.1%-12.3%) isolates. No very major errors were recorded. The CA was 92.9% (95% CI " 86.5%-96.3%). A scatterplot of zone diameters from disc diffusion AST versus MICs from BMD is shown in Figure 3 .
Discussion
The main findings of our study are relatively high susceptibility rates to ceftolozane/tazobactam (66.1%). Resistance was associated with ST235, frequently carrying bla IMP .
Ceftolozane/tazobactam resistance rates differed significantly between MDR (4.8%) and XDR P. aeruginosa (50%; Table 1 ). A similar trend towards lower resistance rates for ceftolozane/tazobactam in MDR was also shown in a Europe-wide collection of 2191 P. aeruginosa. In that study, ceftolozane/tazobactam resistance was 46.8% and 57.2% in MDR and XDR isolates, respectively, applying a clinical breakpoint of 4/4 mg/L. 16 In our study, ceftolozane/tazobactam resistance was often associated with bla IMP (22.3%) . This is in contrast to an analysis mainly representing isolates from Eastern Europe and Russia, where bla VIM (23%), bla OXA -like genes (20.1%) and bla GES (8.6%) were predominant. 16 Similarly, bla IMP (2%) was also rarely detected among carbapenem-resistant P. aeruginosa from Canada. 8 In eight ceftolozane/tazobactam-resistant isolates we did not detect any of Ceftolozane/tazobactam-resistant P. aeruginosa JAC the tested bla genes. Since an OprD porin loss, hyperexpression of MexAB/OprM efflux pumps and AmpC are reportedly not associated with ceftolozane/tazobactam resistance, the underlying mechanism of resistance remains unclear in these cases. 17, 18 Although our strain collection was quite diverse, resistance to ceftolozane/tazobactam was almost exclusively associated with ST235 (19/26 ceftolozane/tazobactam-resistant isolates; Figure 2) .
A low diversity among MDR and XDR P. aeruginosa seems to be common. 19 The ST235 clone is considered to be a high-risk clone due to its worldwide dissemination and its high capacity to take up horizontally transferable resistance genes. 19 In our study, the gradient diffusion test slightly overestimated the ceftolozane/tazobactam resistance. Interestingly, a recent study has shown considerably more susceptible results with Figure 2 . Phylogenetic tree of MDR and XDR P. aeruginosa. The allelic profiles of the cgMLST scheme for P. aeruginosa were used to construct a minimum spanning tree of 77 randomly selected isolates. The MLST ST is shown for each isolate. The size of the nodes corresponds to the number of isolates. Each node represents a unique genotype (i.e. the allelic profile of the isolate based on up to 3842 target genes) determined with the 'pairwise ignoring missing values' option as implemented in SeqSphere ! .
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gradient diffusion methods than with BMD. 20 This discrepancy may be due to our product coming from a different manufacturer. 20 Differences in test results can be associated with different manufacturers of gradient diffusion tests and Mueller-Hinton agar batches. 21 Although our study provides valuable insights into the population of ceftolozane/tazobactam-resistant MDR and XDR P. aeruginosa, some limitations need to be addressed. First, we were unable to identify the presumptive mechanism in eight ceftolozane/tazobactam-resistant isolates even though we screened for 24 MBLs, including MBLs that are only found in environmental bacteria (e.g. bla THIN-B , bla FEZ ). This might be due to a hitherto unknown mechanism of ceftolozane/tazobactam resistance. Second, only isolates from one tertiary care hospital were included which might result in a bias due to in-hospital clonal expansion of a few lineages. On the one hand, we rate the clonal bias as low as our collection covers four years and includes epidemiologically unrelated isolates from colonization and infection derived from different wards of various levels of care. On the other hand, we found a high proportion of bla IMP , which is uncommon in Europe and might mirror a horizontal gene transfer of bla IMP among clonally unrelated P. aeruginosa. Third, higher numbers of truly resistant strains (n 48), as determined by the reference method (BMD), are necessary to completely rule out unacceptably high very major error rates according to US FDA recommendations. 22 In conclusion, ceftolozane/tazobactam resistance is low in MDR P. aeruginosa, but higher in XDR P. aeruginosa, due to the presence of carbapenemases in XDR isolates. The disc diffusion method provided acceptable accuracy for ceftolozane/tazobactam AST. Ceftolozane/tazobactam-resistant P. aeruginosa JAC
